Last reviewed · How we verify

NCT05475756

Safety and Efficacy of Intrauterine Biological Barrier on Postoperative Adhesion After Hysteroscopic Adhesiolysis

Status unknown NA Last updated 27 July 2022
What this trial tests

NA trial testing Intrauterine Biological Barrier in Intrauterine Adhesion in 264 participants. Status unknown.

Timeline
25 February 2022
Primary endpoint
24 May 2024
23 May 2025

Quick facts

Lead sponsorBeijing Tiantan Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeprevention
Enrollment264
Start date25 February 2022
Primary completion24 May 2024
Estimated completion23 May 2025
Sites6 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Tiantan Hospital

Who can join

Adults 20 to 40, female only, with Intrauterine Adhesion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and efficacy of Intrauterine Biological Barrier developed and produced by Chengdu TopRegMed Medical Technology Co., Ltd on postoperative adhesion after Hysteroscopic Adhesiolysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Intrauterine Adhesion

Currently open trials in the same condition.

Other Beijing Tiantan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05475756.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing